Effect of tamsulosin for reduction of lower urinary tract symptoms after double J stent insertion

Noor D. Aziz

University of Kerbala, college of Pharmacy, clinical pharmacy department

Key words:- Double J stent, lower urinary tract symptoms, Tamsulosin

Abstract:

Ureteral stent implantation is a common procedure in urological practice, due to the development in endourological procedures and extracorporeal shock wave lithotripsy. Problems following stent insertion such as stent-related symptoms, migration, fragmentation and encrustation of the stent. The level of complications differs among patients, but mostly it will affect quality of life. $\alpha_1$-Adrenergic receptors have been expressed in the human ureter, and specially in the distal ureter. $\alpha_1$ blockers dilate the lumen and decrease spasms leading to improve stent-related symptoms. The present study was done to evaluate the effect of tamsulosin in improving lower urinary tract symptoms in patients with double-J ureteral stents implantation. This prospective study was performed in Iraq-Babylon in the period from July 2016 to December 2016. Forty eight patients were enrolled in this study all patients completed the follow up period which was 2 weeks, range of age was (25-50) years. The patients were divided into 2 groups: Group 1: consists of (24) patients include (10) males (14) females were treated with double J stent insertion and analgesic on need without Tamsulosin. Group 2: consists of (24) patients include (13) males (11) females were treated with double J stent insertion and drug therapy (tamsulosin 0.4 mg) daily(by oral rout) for 2 weeks. The results show that there was a significant improvement in lower urinary tract symptoms after the treatment period in the second group of patients (p<0.01), while the first group of the patients without tamsulosin use experience the lower urinary tract symptoms for longer duration. The results also reveal that there is no significant relationship between the patients age and gender with the incidence of lower urinary tract symptoms (p>0.01). In conclusion the use of tamsulosin 0.4 mg daily for 14 days is a safe and well tolerated for stent-related symptoms improvement.
INTRODUCTION

Urinary tract “Double J” stent (JJ) is a thin, hollow tube placed inside the ureter during surgery to ensure drainage of urine from the kidney into the bladder. J shaped curls are present at both ends to hold the tube in place and prevent migration, it allows the kidney to drain urine by temporarily relieving any blockage, or to assist the kidney in draining stone fragments freely into the bladder if definitive kidney stone surgery is carried out [1]. In spite of thousand advances in stent biomaterials and structure, JJ stents are not free of complications and problems and the search for an ideal JJ stent may remain until this time. JJ stents are usually made from silicon or polyurethran. Ideal stent characteristics are easy insertion, completely internal placement, resistance to migration, easy removing, radiopacity, biological insertion, and chemical stability, resistance to encrustations, excellent flow characteristics and reasonable price [2]. Stents are used in temporary situations and must be removed from the body. Occasionally, some events occur where communication and follow
Complications including stent encrustation, stone formation, fragmentation and migration. Stent migration is an uncommon complication. It may occur proximally near the kidney or distally near the bladder. Contributors related to distal stent migration include design and stent material. Stents with a complete coil are less subjected to migrate than those with a J-shape [3].

Factor related to proximal stent migration is stent length. Proximal migration occurs when the stent is too small for the ureter; therefore an adequate choice of the stent length is recommended [4].

Various explanations were proposed to explain the stent breakage. Interaction with urine and extensive inflammatory reaction in situ may play an important role in the initiation and promotion of degradation [5].

Common risk factors for stent encrustations are long indwelling time, urinary sepsis, history of stone disease, chemotherapy, pregnancy, chronic renal failure and metabolic or congenital abnormalities [6].

Stent insertion believed to affect over 80% of patient result in stent discomfort and can vary from one patient to another in an idiosyncratic manner [11],[12]. Several studies in literature describe the symptoms related to ureteral stents such as irritative voiding symptoms including frequency, urgency, dysuria, flank and suprapubic pain, incontinence, and hematuria are included [3],[4]. Stent length seems to play a relevant role in stent-related symptoms since it is directly related to bladder irritation. Many different ways to assess the perfect stent length have been suggested [9].

Frequency is attributed to a mechanical irritation that comes from the bladder coil. Together with urgency, it affects a significant proportion of patients 60%. Daytime frequency characterized by the absence of coexisting nocturia suggests that mechanical stimulation relates to physical activities and awareness of this triggering during the day, which would not be noticeable during the night [7].

Urgency is thought to be a direct result from the presence of the stent, which may potentiate pre-existing subclinical detrusor over activity [7]. Dysuria is mainly distinguished at the end of voiding. It was approved that dysuria is secondary due to trigonal irritation by the terminal end of the stent when it pass through the midline or forms an incomplete loop [10].

Flank pain is most likely a result of urine reflux towards the kidney that leads to an excessive rise in intra pelvic pressure that ultimately translates into pain [11],[12]. Suprapubic pain can result from local bladder irritations by the distal coil or as a secondary sign due to complications such as encrustation or infections [13]. Incontinence typically occurs in association with episodes of urgency, or as a result of stent movement beyond the bladder neck into the proximal urethra across the urethral sphincter mechanism of continence [14].

Tamsulosin act by blocking α1A-adrenoceptors in the prostate and also by blocking α1A- and α1D-adrenoceptors in the bladder, which inhibit detrusor muscle contractions. Blocking of adrenergic receptors cause relaxation of bladder neck and prostate smooth muscles.
resulting in improved urine flow rate and limiting lower urinary tract symptoms (LUTS) [15],[16]. Tamsulosin is primarily used for benign prostatic hyperplasia (BPH), but can also assist the passage of kidney stones by the same mechanism of smooth muscle relaxation via alpha antagonism [17].

PATIENTS AND METHODS

This is a prospective follow up study was performed in AL-Hilla teaching hospital in the period from July 2016 to December 2016. 48 patients with double J stent insertion were enrolled in this study; all patients completed the follow up period. Each patient received midazolam I.V. (0.01 mg/kg), ketamine I.V. (0.5 mg/kg), propofol I.V. (2mg/kg), and intubation was done with assist of muscle relaxant rocuronium (0.5 mg/kg) and maintains of anesthesia with isoflurane.

Inclusion criteria patients with double J stent insertion due to different causes. Exclusion criteria were patients with renal or liver dysfunction, hypertension and diabetic.

From each patient the following data were taken: Age, Gender, History, Physical examination as well as Renal and Liver Function Tests. The patients were divided into 2 groups:

- Group 1 consists of (24) patients include (10) males (14) females were treated with double J stent insertion only.
- Group 2 consists of (24) patients include (13) males (11) females were treated with double J stent insertion and drug therapy (tamsulosin 0.4 mg) daily(by oral rout) for 2 weeks. All patients were followed up 2 weeks after treatment.

- **Outcome measures:**
  - For measuring lower urinary tract symptoms, the lower urinary tract symptoms questioner was used.
  - Outcome measures of tamsulosin efficacy include mean changes of frequency, urgency, nocturia, urge incontinence, small voided volume and dysuria from baseline and their corresponding variation.

**Statistical analysis:-**

For continuous data; Mean ± Standard error was implemented.

Mean difference (MD) was used for the continuous outcome data: mean changes for frequency, urgency, urge incontinence, small voided volume, nocturia and dysuria. Data analysis was done by SPSS. Statistical differences were done by using T-test and a \( P\)-value of less than 0.01 was considered as significant.

**RESULTS:-**

Table (1) and (2) show the relation of age and sex respectively with the development of lower urinary tract symptoms, the statistical analysis for these data expressed by (mean ± SE) reveal that there is no significant relationship between the
demographic characteristics of patients’ (age and sex) with the need for double J stent insertion and symptoms development.

**Table 1**: The relation of age with lower urinary tract symptoms (mean ± SE).

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Frequency</th>
<th>Urgency</th>
<th>Nocturia</th>
<th>Urge incontinence</th>
<th>Small voided volume</th>
<th>Dysuria (pain)</th>
</tr>
</thead>
<tbody>
<tr>
<td>25-33</td>
<td>1.4 ±0.18</td>
<td>0.6 ±0.18</td>
<td>0.4 ±0.18</td>
<td>1.0 ±0.26</td>
<td>1.25 ±0.16</td>
<td>0.75 ±0.31</td>
</tr>
<tr>
<td>34-40</td>
<td>1.13 ±0.12</td>
<td>1.13 ±0.29</td>
<td>0.87 ±0.22</td>
<td>1.0 ±0.27</td>
<td>1.0 ±0.33</td>
<td>0.88 ±0.22</td>
</tr>
<tr>
<td>41-50</td>
<td>1.43 ±0.20</td>
<td>1.14 ±0.34</td>
<td>1.0 ±0.22</td>
<td>0.86 ±0.26</td>
<td>1.29 ±0.18</td>
<td>1.0 ±0.22</td>
</tr>
</tbody>
</table>

**Table 2**: The relation of sex with lower urinary tract symptoms (mean ± SE).

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Frequency</th>
<th>Urgency</th>
<th>Nocturia</th>
<th>Urge incontinence</th>
<th>Small voided volume</th>
<th>Dysuria (pain)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>1.23 ±0.12</td>
<td>1.15 ±0.25</td>
<td>0.62 ±0.18</td>
<td>0.69 ±0.17</td>
<td>1.30 ±0.17</td>
<td>0.84 ±0.19</td>
</tr>
<tr>
<td>Female</td>
<td>1.4 ±0.16</td>
<td>0.7 ±0.15</td>
<td>0.9 ±0.18</td>
<td>1.30 ±0.21</td>
<td>1.0 ±0.2</td>
<td>0.9 ±0.23</td>
</tr>
</tbody>
</table>

Table (3) show the changes in LUTS in patients groups, control group without tamsulosin and tamsulosin group. The results showed that the larger decrease in LUTS occur with tamsulosin treated group which was significantly reduced in tamsulosin treated group with p value <0.01.
Table 3: Changes in lower urinary tract symptoms (LUTS) in patients’ groups (mean ± SE).

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Frequency</th>
<th>Urgency</th>
<th>Nocturia</th>
<th>Urge incontinence</th>
<th>Small voided volume</th>
<th>Dysuria (pain)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (days)</td>
<td>4.5 ±0.16</td>
<td>4.04±0.15</td>
<td>3.8±0.17</td>
<td>3.54±0.18</td>
<td>4.33±0.21</td>
<td>5.41±02</td>
</tr>
<tr>
<td>Tamsulosin group (days)</td>
<td>1.29*±0.09</td>
<td>0.91*±0.16</td>
<td>0.75*±0.12</td>
<td>0.95*±0.14</td>
<td>1.20*±0.13</td>
<td>0.83*±0.14</td>
</tr>
</tbody>
</table>

P value <0.01 (*)Mean significant difference.

Figure (1): Changes in lower urinary tract symptom (frequency) in patients’ groups.

Figure (2): Changes in lower urinary tract symptoms (urgency) in patients groups.

Figure (3): Changes in lower urinary tract symptom (urge incontinence) in patients’ groups.
DISCUSSION:

Ureteric insertion of double J stents are considered an integral part of endoscopic procedures, but the symptoms that result from this procedure such as discomfort and pain impair quality of life (QoL), and many patients consider that this to be the worst part of the procedure. The most commonly occurring symptoms that are flank pain, haematuria, dysuria, frequency, and urgency. The pain and LUTS caused by stent placement have been result from local irritation of the bladder and ureteric mucosa causing smooth muscle spasm and pain also occur due to high pressure ureteric reflux. A unified instrument merging these symptoms was developed to evaluate stent symptoms; the ureteric stent symptoms questionnaire (USSQ) evaluates urinary symptoms, body pain, general health, work performance, sexual matters and additional problems. The Arabic version of the USSQ was previously validated and considered a reliable tool in order to evaluating these symptoms and health-related quality of life in patients with ureteric stents insertion [18]. So, it is used in the present study. It allows for meaningful comparison between the case control without tamsulosin and the case on drug in the ongoing effort to improve stent tolerance. This study focused on some important clinical factors like (demographic data of patients like age and sex in addition to LUTS).
In this study we choose monotherapy selective \( \alpha_1 \) blockers (tamsulosin) and compare the efficacy of this drug by measuring the change in LUTS (like frequency, urgency, nocturia, urge incontinence, voided volume, flank pain and pain during voiding) before and after drug administration.

The results were as followed:

**The Relationship between the Demographic Parameters of the Patients (age and sex) and the Incidence of Lower Urinary Tract Symptoms after double J stent insertion:**

The results of this study showed that there is no significant relationship between demographic parameters of patients (age and sex) and the occurrence of LUTS as comparing the results of control group with the result of (tamsulosin) group. Using T-test and P value <0.01

There is no such study that compare the demographic parameters (age and sex) of the patients with the incidence of LUTS.

**Comparing The effect of selective \( \alpha_1 \) blockers (tamsulosin) on lower urinary tracts symptoms with the control group:**

The results of this study showed that tamsulosin (0.4 mg/day) oral administration for two weeks post operative reduces the incidence of frequency, urgency, urge incontinence, small voided volume, dysuria and nocturia significantly when comparing the results of control group with the results of second group (on tamsulosin) after drug administration.

These results agree with Wang et al., [19] reported a prospective, randomized study comparing tamsulosin with placebo in 79 patients with double-J stents and found that tamsulosin improved stent-related symptoms and quality of life, and could be applied in routine clinical practice. Also Damiano et al., [20] demonstrated the positive effect of tamsulosin 0.4 mg once daily in improving stent-related urinary symptoms and pain after 1 week of drug use.

Previous studies by Joshi et al., [21]. Coyne et al., [22]. had found an association between the ureteric stent symptoms (USSs) and patients’ quality of life and this study also indicated the association, as the improved quality of life may be mainly contributed by the improved urinary symptom and pain index.

**CONCLUSION:**

In conclusion, the use of tamsulosin 0.4 mg (oral rout) daily for 14 days is a safe and well tolerated for stent-related symptoms improvement after double J stent insertion.

**ACKNOWLEDGMENTS**

Author is thankful to Assist. Prof. Dr. Muhammad R. Judi and Dr. Abbas F. Alhussaini for sharing their knowledge, and all who participates in this work.
REFERENCES


